Drugs / ASP2802
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06248086 | Sep → Dec 2024 | neoplasm of mature B-cells | Astellas Pharma Global Development, Inc. | Terminated | No outcome recorded Stop: Business |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ASP2802 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06248086 ↗ |
| Modality | Cell therapy | “ASP2802 is a type of CAR-T cell therapy” NCT06248086 ↗ |